Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kenjiro Kishitani"'
Autor:
Hayato Hoshina, Satoru Taguchi, Hikaru Suyama, Kenjiro Kishitani, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Naoya Akiba, Keiichi Kumasawa, Mayuyo Mori-Uchino, Yutaka Osuga, Haruki Kume
Publikováno v:
BMC Urology, Vol 23, Iss 1, Pp 1-5 (2023)
Abstract Background Management of a bladder tumor during pregnancy is an uncommon clinical situation. Leiomyosarcoma of the urinary bladder is a rare histological type of bladder tumor and a rare secondary cancer in survivors of retinoblastoma (RB).
Externí odkaz:
https://doaj.org/article/cce8686b4d574a9a9d9f07ceee92fbbf
Autor:
Kenjiro Kishitani, Kenji Yoda, Satoru Taguchi, Hikaru Suyama, Hayato Hoshina, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Haruki Kume
Publikováno v:
IJU Case Reports, Vol 6, Iss 1, Pp 56-59 (2023)
Introduction Testicular ectopia refers to abnormal positioning of testis, which includes a wide variety of variants. An ectopic testis is located off the normal path of male gonadal descent, unlike conventional undescended testis. Case presentation A
Externí odkaz:
https://doaj.org/article/fa42335728974e67a034f0c631b0f281
Autor:
Kazuma Sugimoto, Satoru Taguchi, Kenjiro Kishitani, Taketo Kawai, Kazuki Masuda, Yu Nakamura, Manami Kinjo, Mitsuhiro Tambo, Jimpei Miyakawa, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Tohru Nakagawa, Hiroshi Fukuhara, Haruki Kume
Publikováno v:
BMC Urology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background While gemcitabine/cisplatin (GC) is the gold standard regimen for patients with advanced urothelial carcinoma (aUC), either dose-reduced GC or gemcitabine/carboplatin (GCa) is an alternative option for “cisplatin-unfit” patien
Externí odkaz:
https://doaj.org/article/18e17e7885da4a46b1c137ccd711619c
Autor:
Kenjiro Kishitani, Kenji Yoda, Satoru Taguchi, Hikaru Suyama, Hayato Hoshina, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Haruki Kume
Publikováno v:
IJU Case Reports. 6:56-59
Autor:
Satoru Taguchi, Taketo Kawai, Sebastiano Buti, Melissa Bersanelli, Yukari Uemura, Kenjiro Kishitani, Jimpei Miyakawa, Kazuma Sugimoto, Yu Nakamura, Fusako Niimi, Tomoyuki Kaneko, Jun Kamei, Daisuke Obinata, Kenya Yamaguchi, Shigenori Kakutani, Koichiro Kanazawa, Yuriko Sugihara, Mayuko Tokunaga, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Yutaka Enomoto, Hiroaki Nishimatsu, Tetsuya Fujimura, Hiroshi Fukuhara, Tohru Nakagawa, Satoru Takahashi, Haruki Kume
Publikováno v:
Immunotherapy.
Aim: To validate a ‘drug score’ that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC). Materials & methods: We assessed oncological outc
Autor:
Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, Jimpei Miyakawa, Kenjiro Kishitani, Kazuma Sugimoto, Yu Nakamura, Jun Kamei, Daisuke Obinata, Kenya Yamaguchi, Tomoyuki Kaneko, Kanae Yoshida, Sachi Yamamoto, Shigenori Kakutani, Koichiro Kanazawa, Yuriko Sugihara, Mayuko Tokunaga, Akihiko Matsumoto, Yukari Uemura, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Yutaka Enomoto, Hiroaki Nishimatsu, Akira Ishikawa, Yoshinori Tanaka, Yasushi Nagase, Tetsuya Fujimura, Hiroshi Fukuhara, Satoru Takahashi, Haruki Kume
Publikováno v:
International journal of urology : official journal of the Japanese Urological AssociationREFERENCES.
Although the treatment strategy for advanced urothelial carcinoma (aUC) has drastically changed since pembrolizumab was introduced in 2017, studies revealing current survival rates in aUC are lacking. This study aimed to assess (1) the improvement in